Early glycan screening is a cornerstone for ensuring long-term biologic quality and accelerating decision-making in cell line development (CLD). Glycan profiles, as a critical quality attribute, play a pivotal role in therapeutic efficacy, stability and safety.
This webinar explores how high-throughput glycan screening integrates into the broader Solentim ecosystem for CLD automation, reducing manual effort while providing scientists with rapid, actionable clone data.
Attendees will learn from different case studies on biosimilars and glycan-engineered antibodies, discovering how automated workflows improve accuracy and efficiency while eliminating unnecessary clone progression. Whether new to CLD or optimizing existing workflows, this webinar offers practical strategies to drive biologic excellence through early glycan insights.
Register for this webinar today to discover how early glycan screening is revolutionizing cell line development by ensuring biologic quality and accelerating decision-making.
Speakers

Sebastian Giehring, CEO, PAIA
Sebastian Giehring earned his PhD in Analytical Chemistry from the University of Hamburg in 1999. He subsequently worked in a scientific role at a spectrometry company before transitioning to a venture capital firm as an investment manager for life sciences.
In 2006, he chose to pursue the startup sector, taking on various management roles in life science tool companies. In 2014, he invented the PAIA microplate technology and founded PAIA Biotech GmbH, where he has served as CEO ever since.

Andrea Gough, Senior Director, Solentim Portfolio
Andrea Gough is the Senior Director for the Solentim Portfolio at Advanced Instruments. With a first-class bachelor’s degree in applied Biochemistry and Molecular Cell Biology from the University of the West of England, Andrea has over 15 years of experience in biologic drug development, specializing in cell line development (CLD). She began her career as a Field Application Scientist at Molecular Devices, supporting customers with CLD challenges and automation implementation.
Andrea has since held global product management roles at Thermo Fisher Scientific, Solentim, and Horizon Discovery. At Advanced Instruments, she progressed from Senior Business Development Manager to Senior Director, focusing on enhancing CLD efficiencies through the AI Solentim portfolio.
Who Should Attend?
This webinar will appeal to:
- Scientists and managers working in CLD or considering internalizing CLD processes
- Those focused on protein-based therapies and looking to optimize their CLD workflows
- Professionals ensuring CQAs like glycan profiles meet stringent regulatory standards
- Teams seeking innovative, high-throughput solutions to improve biologics development and manufacturing efficiency
What You Will Learn
Attendees will learn about:
- The importance of early glycan screening for ensuring biologic quality
- How automation reduces time-to-insight and improves workflow efficiency
- Real-world applications and results from glycan screening success
- How to integrate automated glycan profiling into CLD labs
Xtalks Partner
Advanced Instruments
Advanced Instruments is a global provider of scientific and analytical instruments for the bioprocessing and clinical industries. For nearly 70 years, the company’s innovations have helped organizations improve quality of results, achieve reliable outcomes, and increase workplace productivity. Clinical labs worldwide rely on Advanced Instruments’ innovative solutions for delivery of accurate and timely patient results in their clinical chemistry, microbiology, and hematology labs. For more information, visit www.aicompanies.com.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account